Funded Biotechnology Startups
The 16 most recent funding rounds in biotechnology, healthcare, and pharmaceuticals span late September through late November 2025, with Series A the domin…
The 16 most recent funding rounds in biotechnology, healthcare, and pharmaceuticals span late September through late November 2025, with Series A the dominant stage — five companies closed Series A rounds in this window, ranging from T-Therapeutics' $32M in Cambridge, UK to Braveheart Bio's $185M (location undisclosed). Seed-stage activity is also present, with four companies raising at that stage, including Nuclide Therapeutics ($7M, London) and Athernal Bio ($5M, Cambridge, UK), pointing to continued early-stage pipeline investment in the UK biotech corridor.
US cities account for the majority of disclosed locations — Boston, Berkeley, Cambridge, Palo Alto, South San Francisco, Natick, Doylestown, New York, and Syracuse all appear — while international rounds include Lyon (Ventuno Biotech, $2M seed), Donostia-San Sebastián (Adaptam Therapeutics, $3M pre-seed), and Shanghai (Immunofoco, Series B, undisclosed). Three of the 16 rounds carry undisclosed amounts; the remaining 13 range from $2M to $185M.
Most recent rounds
16 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Braveheart Bio leads with a $185M Series A (location undisclosed), followed by Zag Bio at $80M (Series A, Cambridge MA), Excellergy at $70M (Series A, Palo Alto), Cartography Biosciences at $67M (Series B, South San Francisco), and Azalea Therapeutics at $65M (Series A, Berkeley). All five of the top rounds by size are Series A or Series B.
Which funding stage appears most frequently among these recent biotech rounds?
Series A accounts for five of the 16 rounds — T-Therapeutics ($32M, Cambridge UK), Azalea Therapeutics ($65M, Berkeley), Braveheart Bio ($185M), Zag Bio ($80M, Cambridge MA), and Excellergy ($70M, Palo Alto). Four rounds are labeled Venture - Series Unknown and four are Seed-stage.
Where are most of these funded biotech companies headquartered?
US cities dominate: Boston, Berkeley, Cambridge MA, Palo Alto, South San Francisco, Natick, Doylestown, New York, and Syracuse each host at least one company. The UK is the leading non-US cluster, with T-Therapeutics and Athernal Bio both in Cambridge UK and Nuclide Therapeutics in London.
Are there any biotech rounds outside the US and UK in this data?
Three rounds fall outside the US-UK corridor: Ventuno Biotech closed a $2M seed in Lyon, France; Adaptam Therapeutics raised a $3M pre-seed in Donostia-San Sebastián, Spain; and Immunofoco completed an undisclosed Series B in Shanghai, China.
How many rounds in this dataset have undisclosed amounts?
Three rounds — Eliksa Therapeutics (Doylestown), Immunofoco (Shanghai), and Nionyx Bio (New York) — list undisclosed amounts. The remaining 13 disclose figures ranging from $2M (Ventuno Biotech seed, Lyon) to $185M (Braveheart Bio Series A).
What time window do these 16 rounds cover?
The rounds span from September 26, 2025 (Nuclide Therapeutics seed, London) through November 28, 2025 (Repair Biotechnologies venture, Syracuse) — roughly a two-month window of disclosed biotech funding activity.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.